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Shared decision making: patients have a right to
be informed about possible treatment options
and their risks and benefits
Rosca Ana, Krones Tanja, Biller-Andorno Nikola
Institute of Biomedical Ethics and History of Medicine, University of Zurich, University Hospital Zurich, Switzerland
Historically, physicians liked to refer to the so-called ther-
apeutic privilege when withholding information they con-
sidered too distressing for their patients. A broad inter-
pretation of this principle allowed physicians to inform or
not inform patients at their discretion. These days are long
gone. The therapeutic privilege is explicitly rejected by or-
ganisations such as the American Medical Association [1].
The code of the Swiss Medical Association emphasises the
duty to inform patients, although it still leaves some room
for interpretation as to how much information physicians
think their patients can bear and how their patients should
best be informed [2].
More recently, the concept of shared decision making
(SDM) as a guide to patient-centred information and care
has become prevalent in Switzerland [3–5]. The concept
was at the centre of the recent “Excellence in Patient Care”
symposium hosted by the Collegium Helveticum and or-
ganised by the University of Zurich, the University Hospi-
tal Zurich and the University Hospital Basel [6].
SDM can be defined as an interpersonal, interdependent
process in which physicians, patients and their caregivers
relate to and influence each other as they collaborate to
make decisions about a patient’s healthcare [7]. The
process becomes relevant whenever the risks and benefits
of more than one treatment option need to be compared.
The SDM model proposed by Jurgen Kasper and his team
(fig. 1) describes the generic core of the SDM process.
Since its early days in the 1990s [9], SDM has reached be-
yond the dyad of patient and healthcare professionals to
include specialised nurses, specialist physicians and other
healthcare professionals. It has been suggested that SDM
best practice should involve “team talk”, “option talk” and
“decision talk”, with the aim of improving the process
of deliberation and collaboration between all the parties
involved [10]. At the “team talk” level, all the involved
healthcare professionals deliberate the medical options for
treating the patient. The “option talk” takes place with the
patient and includes one or more talks with the GP, nurs-
es and/or clinical specialists, while the final “decision talk”
takes place between the patient and the healthcare profes-
sional who will deliver the treatment. This complex model
is a valuable aspirational goal that can overcome numer-
ous challenges, both procedural and conceptual, in real-life
clinical settings.
From a provider perspective, it could be argued that in
many instances there is no need to negotiate with the pa-
tient, as there are guidelines that tell physicians what
should be done. This might be true in “black” situations,
when there is high-quality evidence that an intervention is
likely to do no good or even more harm than good. In these
cases the intervention would not be appropriate. Negotia-
tions might also seem unnecessary in “white” situations,
when an intervention is likely to do more good than harm,
although in these cases the patient must still consent to the
treatment and may well reject it no matter what the guide-
lines say. However, it has been argued that the large ma-
jority of clinical evidence is “grey” [11]: the evidence is
either lacking, supports more than one option (equipoise)
or of low quality. In such scenarios, decisions should be
preference-sensitive, i.e. they should depend on personal
judgments concerning how the benefits and risks should be
weighed.
Furthermore, some patients may not want their physicians
to interfere with what could be seen as a private choice.
And indeed, just as physicians can decline non-emergency
treatments they do not feel comfortable offering, compe-
tent patients have the right to be left alone when making
healthcare decisions. In most cases, however, patients will
seek personalised information, and often personal coun-
selling and advice as well, from their physicians.
When discussing options, benefits and harms, uncertain-
ties, and preferences, physicians should engage with their
patients as partners. In an SDM process, patients commu-
nicate their individual and often unpredictable preferences;
they share their knowledge about their health and body
while considering medical information and the provider’s
preferences. The physicians try to align patient preferences
with the available evidence and, if relevant, their own
stance. If their patient’s choice is not compatible with what
they consider responsible care, they do not need to offer it.
This process is particularly important and challenging in
the case of multimorbid patients, in which one decision
can have an impact on more than one treatment process.
One important reason why SDM is not yet easily applic-
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Figure 1: Shared decision-making process [8].
able to multimorbid patients is the low inclusion rate of
this patient group in clinical trials [12, 13]. Because of
the limited evidence for multimorbid patients, SDM often
cannot do justice to the complexity of treating this group.
Another challenge is that addressing multiple issues at the
same time can be overwhelming for both the patient and
the physician. One approach to this problem is to address
just one aspect of care at a time. There are, for instance,
decision aids for diabetes that allow patients to decide
which aspect of their complex medical care (like lowering
blood sugar, lowering blood pressure, lowering the glycat-
ed haemoglobin, weight control) they want to focus on dur-
ing a particular visit [14]. This could also mean that during
that visit only one single aspect (e.g., weight control) will
be discussed. Over time, all these aspects will be addressed
and clarified.
The complexity of treating multimorbid patients increases
when more healthcare teams are involved. This also in-
creases the complexity of SDM implementation. All par-
ticipants (including the patient and/or, if applicable, their
surrogate) must have the chance to share their own prefer-
ences and to hear those of the other parties involved. This
kind of complex, interdisciplinary approach is rarely easy
to implement [15], and requires the top-down support of
system and process changes. There are examples which
show that an interdisciplinary approach is feasible and not
overly resource intensive. The existence of various expert
boards (e.g., tumour or heart boards) can serve as a start-
ing point for the implementation of an interdisciplinary and
interprofessional SDM process. The aim of such boards is
to determine the best available treatment for individual pa-
tients. If the patient expresses a strong preference for a spe-
cific treatment plan, this will be considered during board
discussions. An interdisciplinary SDM best practice would
create enough opportunity for jointly discussing the prefer-
ences and needs of the patients and their surrogates (if nec-
essary), as well as the expertise and preferences of the in-
volved physicians (including those from other disciplines).
If this is not possible, the preferences of each of the in-
volved parties should be collected and brought up during
interdisciplinary board meetings.
General practitioners (GPs) can play an important role in
ensuring that the preferences of all patients, including mul-
timorbid ones, are given due consideration. GPs usually
have a holistic view of their patients’ existing conditions,
have usually had prolonged contact with them and are usu-
ally acquainted with their preferences regarding the vari-
ous treatments of their comorbidities. They can therefore
focus not only on a specific treatment but on the gener-
al goals of care, and best summarise and transfer to the
specialised clinicians the information required for mak-
ing decisions. If the SDM process is performed by GPs,
the preferences of their patients concerning one treatment
will already be balanced against other existing conditions.
The systematic reporting of patient preferences – regarding
both goals of care and treatment options – can help both
GPs and specialised physicians deliver individualised care.
In summary, SDM is a key concept in the process of work-
ing towards high-quality, patient-centred care for all pa-
tient populations. It is relevant not only for current care de-
cisions, but also for advance care planning, and it is needed
particularly during times of crisis such as we are seeing
currently with COVID-19: while we rightly focus on sav-
ing lives and protecting the vulnerable groups of the elder-
ly and the chronically ill, we should always ensure that we
not only do not neglect patients, but that we also do not im-
pose on them treatments that they do not want. When deal-
ing with a frail patient who has contracted pneumonia due
to an unexpected infection (e.g., COVID-19), discussing in
a sensitive, professional way how far treatment should go
if the situation gets worse (intensive care, intubation, re-
animation etc.), is a perfect illustration of shared decision
making.
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